Your search for evid returned 4446 results

Novo Nordisk plans to file for regulatory approval of the 25mg and 50mg dosage strengths in 2023.

Treatment with dupilumab led to a significant 30% reduction in moderate or severe acute COPD exacerbations.

Tofersen is an investigational antisense medicine that reduces the synthesis of SOD1 protein production.

Rezzayo is expected to be available in the summer of 2023.

Pulmonary function tests may be beneficial every six months, may be of use in initiating noninvasive ventilation when indicated

An FDA panel has voted in favor of the safety and effectiveness of Paxlovid for COVID-19.

Higher genetically predicted plasma caffeine concentrations linked to lower risk for type 2 diabetes, with 43% of effect mediated by BMI.

Multifaceted intervention of assessment, education, and feedback increases likelihood of triple prescription fourfold over usual care

Some clinically meaningful improvements seen compared with education or inactive control

Previously, the treatment had been approved for patients 1 year of age and older.